Limits...
A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions.

Martins CL, Benn CS, Andersen A, Balé C, Schaltz-Buchholzer F, Do VA, Rodrigues A, Aaby P, Ravn H, Whittle H, Garly ML - J. Infect. Dis. (2014)

Bottom Line: For children who had not received NVAS, the admission HRR was 0.53 (95% CI, .34-.84), with an effect of 0.30 (95% CI, .13-.70) for girls and 0.73 (95% CI, .42-1.28) for boys (P = .08, interaction test).The reduction in admissions was separately significant for measles infection (admission HRR, 0 [95% CI, 0-.24]) and respiratory infections (admission HRR, 0.37 [95% CI, .16-.89]).Early measles vaccine may have major benefits for infant morbidity patterns and healthcare costs.

View Article: PubMed Central - PubMed

Affiliation: Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.

ABSTRACT
Observational studies and trials from low-income countries indicate that measles vaccine has beneficial nonspecific effects, protecting against non-measles-related mortality. It is not known whether measles vaccine protects against hospital admissions. Between 2003 and 2007, 6417 children who had received the third dose of diphtheria, tetanus, and pertussis vaccine were randomly assigned to receive measles vaccine at 4.5 months or no measles vaccine; all children were offered measles vaccine at 9 months of age. Using hospital admission data from the national pediatric ward in Bissau, Guinea-Bissau, we compared admission rates between enrollment and the 9-month vaccination in Cox models, providing admission hazard rate ratios (HRRs) for measles vaccine versus no measles vaccine. All analyses were conducted stratified by sex and reception of neonatal vitamin A supplementation (NVAS). Before enrollment the 2 groups had similar admission rates. Following enrollment, the measles vaccine group had an admission HRR of 0.70 (95% confidence interval [CI], .52-.95), with a ratio of 0.53 (95% CI, .32-.86) for girls and 0.86 (95% CI, .58-1.26) for boys. For children who had not received NVAS, the admission HRR was 0.53 (95% CI, .34-.84), with an effect of 0.30 (95% CI, .13-.70) for girls and 0.73 (95% CI, .42-1.28) for boys (P = .08, interaction test). The reduction in admissions was separately significant for measles infection (admission HRR, 0 [95% CI, 0-.24]) and respiratory infections (admission HRR, 0.37 [95% CI, .16-.89]). Early measles vaccine may have major benefits for infant morbidity patterns and healthcare costs. Clinical trials registration NCT00168558.

Show MeSH

Related in: MedlinePlus

The cumulative incidence of hospital admissions, according to randomization group. Early recipients received measles vaccine at 4.5 and 9 months of age, and controls received vaccine at 9 months of age.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4017359&req=5

JIT804F1: The cumulative incidence of hospital admissions, according to randomization group. Early recipients received measles vaccine at 4.5 and 9 months of age, and controls received vaccine at 9 months of age.

Mentions: We enrolled children between August 2003 and April 2007. The study profile has been described previously ([13] Figure 1); 2129 were randomly assigned to receive EZ measles vaccine at 4.5 and 9 months of age, and 4288 were randomly assigned to receive no vaccine at 4.5 months of age. There were no major differences in demographic, socioeconomic, and health related background factors for the early receipt group and the control group ([13] Table 1). The median age at the 9-month measles vaccine was 274 days (interquartile range, 271–278 days) in the early receipt group and 273 days (271–276 days) in the control group. Furthermore, there was no difference in hospital admissions before enrollment (relative risk [RR], 1.03 [95% CI, 0.80–1.33]). Between enrollment and the 9-month measles vaccine, 221 hospital admissions were detected.Table 1.


A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions.

Martins CL, Benn CS, Andersen A, Balé C, Schaltz-Buchholzer F, Do VA, Rodrigues A, Aaby P, Ravn H, Whittle H, Garly ML - J. Infect. Dis. (2014)

The cumulative incidence of hospital admissions, according to randomization group. Early recipients received measles vaccine at 4.5 and 9 months of age, and controls received vaccine at 9 months of age.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4017359&req=5

JIT804F1: The cumulative incidence of hospital admissions, according to randomization group. Early recipients received measles vaccine at 4.5 and 9 months of age, and controls received vaccine at 9 months of age.
Mentions: We enrolled children between August 2003 and April 2007. The study profile has been described previously ([13] Figure 1); 2129 were randomly assigned to receive EZ measles vaccine at 4.5 and 9 months of age, and 4288 were randomly assigned to receive no vaccine at 4.5 months of age. There were no major differences in demographic, socioeconomic, and health related background factors for the early receipt group and the control group ([13] Table 1). The median age at the 9-month measles vaccine was 274 days (interquartile range, 271–278 days) in the early receipt group and 273 days (271–276 days) in the control group. Furthermore, there was no difference in hospital admissions before enrollment (relative risk [RR], 1.03 [95% CI, 0.80–1.33]). Between enrollment and the 9-month measles vaccine, 221 hospital admissions were detected.Table 1.

Bottom Line: For children who had not received NVAS, the admission HRR was 0.53 (95% CI, .34-.84), with an effect of 0.30 (95% CI, .13-.70) for girls and 0.73 (95% CI, .42-1.28) for boys (P = .08, interaction test).The reduction in admissions was separately significant for measles infection (admission HRR, 0 [95% CI, 0-.24]) and respiratory infections (admission HRR, 0.37 [95% CI, .16-.89]).Early measles vaccine may have major benefits for infant morbidity patterns and healthcare costs.

View Article: PubMed Central - PubMed

Affiliation: Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.

ABSTRACT
Observational studies and trials from low-income countries indicate that measles vaccine has beneficial nonspecific effects, protecting against non-measles-related mortality. It is not known whether measles vaccine protects against hospital admissions. Between 2003 and 2007, 6417 children who had received the third dose of diphtheria, tetanus, and pertussis vaccine were randomly assigned to receive measles vaccine at 4.5 months or no measles vaccine; all children were offered measles vaccine at 9 months of age. Using hospital admission data from the national pediatric ward in Bissau, Guinea-Bissau, we compared admission rates between enrollment and the 9-month vaccination in Cox models, providing admission hazard rate ratios (HRRs) for measles vaccine versus no measles vaccine. All analyses were conducted stratified by sex and reception of neonatal vitamin A supplementation (NVAS). Before enrollment the 2 groups had similar admission rates. Following enrollment, the measles vaccine group had an admission HRR of 0.70 (95% confidence interval [CI], .52-.95), with a ratio of 0.53 (95% CI, .32-.86) for girls and 0.86 (95% CI, .58-1.26) for boys. For children who had not received NVAS, the admission HRR was 0.53 (95% CI, .34-.84), with an effect of 0.30 (95% CI, .13-.70) for girls and 0.73 (95% CI, .42-1.28) for boys (P = .08, interaction test). The reduction in admissions was separately significant for measles infection (admission HRR, 0 [95% CI, 0-.24]) and respiratory infections (admission HRR, 0.37 [95% CI, .16-.89]). Early measles vaccine may have major benefits for infant morbidity patterns and healthcare costs. Clinical trials registration NCT00168558.

Show MeSH
Related in: MedlinePlus